Centessa Pharmaceuticals plc

General Information
Business:

We are reimagining the traditional pharmaceutical research and development model to build, from the bottom-up, an R&D engine predicated on asset centricity to discover, develop and ultimately deliver impactful medicines to patients. 

Centessa was formed in October 2020 by Medicxi with a view to ultimately acquiring, and thereby becoming the holding company of, several pre-revenue, development stage biotech companies each of which was either controlled by and/or invested in by a fund affiliated with Medicxi or Index Ventures. On Jan. 29, 2021, Centessa acquired 11 biotechnology companies and simultaneously closed a Series A funding round of $250 million. Prior to the acquisition, Centessa’s activities were limited mainly to engaging advisors and recruitment efforts. Centessa commenced active operations after the consummation of the acquisitions. Each of the Centessa Subsidiaries was a portfolio company of a fund affiliated with Medicxi or Index Ventures at the time of the acquisition.

(Note: Centessa Pharmaceuticals plc upsized its IPO at pricing on May 27, 2021, to 16.5 million American Depositary Shares (ADS), up from 15 million ADS in the prospectus, at $20 – the top of its $18-to-$20 range – to raise $330 million.)

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 34
Founded: 2020
Contact Information
Address 3rd Floor, 1 Ashley Rd, Altrincham, Cheshire, United Kingdom, WA14 2DT
Phone Number +44 7391 789784
Web Address http://www.centessa.com/
View Prospectus: Centessa Pharmaceuticals plc
Financial Information
Market Cap $1632.48mil
Revenues $0 mil (last 12 months)
Net Income $-4.58 mil (last 12 months)
IPO Profile
Symbol CNTA
Exchange NASDAQ
Shares (millions): 16.5
Price range $20.00 - $20.00
Est. $ Volume $330.0 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs
CO-Managers Jefferies/ Evercore ISI
Expected To Trade: 5/28/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change